AzTrials
AzTrials

Dietary ModificationPRECOR-NUTNCT02180035

Treatment With Nutritional Eating Plan and Dietary Fibers in Adult Patients With HIV/AIDS

A study testing Symbiotic and Nutritional intervention in people with Dietary Modification and Dyslipidemia, run by Conselho Nacional de Desenvolvimento Científico e Tecnológico at 1 site in Brazil.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To evaluate if nutritional treatment with nutritional supplementation of dietary fiber reduces cholesterol levels and triglycerides (dyslipidemia) in patients with HIV/AIDS receiving antiretroviral therapy (HAART). Read more about this study

Who is it for?
Ages 19 years and older
What is being tested?
Symbiotic and Nutritional intervention
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
290 participants
Where
1 siteBrazil
Study dates
Oct 2009to Jul 2011
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 19 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • HIV-infected patients
  • Adults (≥ 19 years old)
  • On highly active antiretroviral therapy (HAART)

Who cannot join

  • Pregnancy
  • Breastfeeding
  • Opportunistic disease

Trial locations and contacts

1 site in 1 country.

Brazil1 site
  • Outpatient Infectoparasitary Diseases, Hospital das Clinicas, Federal University of Goiás

    Goiânia, Goiás, 74.605-020

Other trials in Brazil

About this study

Official title: Effect of Treatment Nutritional With Supplementation About Biochemical Profile and Anthropometry in Adult Patients With HIV/AIDS

To evaluate if nutritional treatment with nutritional supplementation of dietary fiber reduces cholesterol levels and triglycerides (dyslipidemia) in patients with HIV/AIDS receiving antiretroviral therapy (HAART).

Being tested
Symbiotic, Maltodextrin (placebo for symbiotic), Nutritional intervention
Keywords
diet therapy, symbiotic, dyslipidemia, gastrointestinal symptoms, body composition, adherence, HIV, HAART
Medical subject headings
Dyslipidemias, Signs and Symptoms, Digestive

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SymbioticDietary supplement

    6g sachet composition: Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus acidophillus, Bifidobacterium lactis and fructooligosaccharides. Each patient was instructed to consume two sachets per day, one in the morning and another before bedtime, diluted in 100 ml of filtered or boiled water at room temperature. The dietary supplement should be taken every day for 6 months.

  • Maltodextrin (placebo for symbiotic)Dietary supplement

    6g sachet of maltodextrin, a complex carbohydrate. Each patient was instructed to consume two sachets per day, one in the morning and another before bedtime, diluted in 100 ml of filtered or boiled water at room temperature. Placebo should be taken daily for 6 months.

  • Nutritional interventionBehavioural

    Nutritional intervention consists of dietary prescription (nutritional eating plan) for healthy eating based on the Dietary Guidelines for the Brazilian Population and Clinical Manual on Food and Nutrition in HIV-infected Adults Care, both Brazil Ministry of Health guidelines, in addition to nutritional counseling for preexistent clinical conditions.

Study groups in NCT02180035
Study groupRoleWhat they receive
Symbiotic & Nutritional interventionExperimentalSymbiotic (dietary fibers + probiotic bacteria) 6g sachet twice daily for 6 months, dietary prescription and nutritional counseling
Receives: Dietary Supplement: Symbiotic; Behavioral: Nutritional intervention
Maltodextrin & Nutritional interventionPlacebo comparatorMaltodextrin (placebo for symbiotic) 6g sachet twice daily for 6 months, dietary intervention and nutritional counseling.
Receives: Dietary Supplement: Maltodextrin (placebo for symbiotic); Behavioral: Nutritional intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Seric lipid levels

    Changes from baseline in total cholesterol, triglycerides, HDL-C and LDL-C.

    Measured: Baseline, Week 24

Secondary outcomes (5)
  1. Fasting blood glucose

    Changes from baseline in fasting blood glucose.

    Measured: Baseline, Week 24

  2. Gastrointestinal symptoms

    Assessment of the presence of gastrointestinal symptoms (nausea and/or vomiting, dyspepsia, heartburn, diarrhea, flatulence and constipation), associated or not with antiretrorival therapy, before and after intervention to verify their effectiveness in reducing these symptoms.

    Measured: Baseline, Week 24

  3. Adherence to the nutritional intervention and nutritional appointments

    Assessment of dietary intake modification after intervention and patient's return to nutritional appointments.

    Measured: Baseline, Week 24

  4. Body composition

    Changes from baseline in total body fat percentage, percentage of fat in the trunk, percentage of fat in the arms, percentage of fat in the legs and lean body mass percentage.

    Measured: Baseline, Week 24

  5. Anthropometric measures

    Changes from baseline in weight, waist circumference, abdominal circumference, waist-to-hip ratio and Body Mass Index (BMI).

    Measured: Baseline, Week 24

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Jul 2014 (estimated)
  2. Study startOct 2009
  3. Primary completionJul 2011
  4. Study completionJul 2011

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Care provider
Enrolment
290 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02180035
Sponsor's protocol ID
CNPq- 478741/2008-1
Acronym
PRECOR-NUT
Status last verified
Jul 2014
First submitted
1 Jul 2014
Last updated
17 Jul 2014
Results posted
No
Data monitoring committee
Yes

Publications

  • Falco M, Castro Ade C, Silveira EA. [Nutritional therapy in metabolic changes in individuals with HIV/AIDS]. Rev Saude Publica. 2012 Aug;46(4):737-46. doi: 10.1590/s0034-89102012005000050. Epub 2012 Jul 10. Portuguese.

    PubMed 22782126
  • Nery MW, Martelli CM, Silveira EA, de Sousa CA, Falco Mde O, de Castro Ade C, Esper JT, Souza LC, Turchi MD. Cardiovascular risk assessment: a comparison of the Framingham, PROCAM, and DAD equations in HIV-infected persons. ScientificWorldJournal. 2013 Oct 21;2013:969281. doi: 10.1155/2013/969281. eCollection 2013.

    PubMed 24228022
  • Santos ASEAC, Silveira EAD, Falco MO, Nery MW, Turchi MD. Effectiveness of nutritional treatment and synbiotic use on gastrointestinal symptoms reduction in HIV-infected patients: Randomized clinical trial. Clin Nutr. 2017 Jun;36(3):680-685. doi: 10.1016/j.clnu.2016.06.005. Epub 2016 Jun 23.

    PubMed 27395330

Questions about this trial

What is this clinical trial studying?

A study testing Symbiotic and Nutritional intervention in people with Dietary Modification and Dyslipidemia, run by Conselho Nacional de Desenvolvimento Científico e Tecnológico at 1 site in Brazil.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 Jul 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Seric lipid levels (time frame: Baseline, Week 24). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02180035, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jul 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in